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Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is an 
immunological pulmonary disease resulting from a hypersensitivity 
to Aspergillus antigens, more specifically to Aspergillus fumigatus (A. 
fumigatus). ABPA definition is sometimes improperly used to define 
hypersensitivity to other Aspergillus species. In that case the appropriate 
definition is allergic bronchopulmonary mycosis (ABPM) clinically 
identical to ABPA but caused by other fungi including Fusarium, 
Schizophyllum, Curvularia and Aspergillus species other than A. 
fumigatus [1]. First reported in detail in 1952 by Hinson et al. [2], ABPA 
occurs mainly as a complication in patients affected by asthma or cystic 
fibrosis (CF) who have been sensitized to A. fumigatus [1] (hereafter, 
asthma-ABPA and CF-ABPA patients). Coexisting atopy is often 
observed in these patients.
Rarely, ABPA occurs in patients with chronic granulomatous 
disease, hyperimmunoglobulinemia E, chronic eosinophilic 
pneumonia, Churg-Strauss syndrome, parasitic infestations, lymphoma 
and in lung transplant recipients [3,4]. An early diagnosis of ABPA, due 
to clinical, serological and radiological findings, is important in order 
to try to prevent lung damage resulting from inadequate or delayed 
therapy. This review is focused on challenges that caregivers can come 
across while diagnosing and treating this disease. A comprehensive 
search was conducted on December 2015 on MEDLINE literature via 
PubMed. Citations were identified on the electronic database using the 
terms “bronchopulmonary aspergillosis” or “ABPA” and “diagnosis” 
and “therapy” or “treatment”. To reduce the risk of missing relevant 
studies, searches were not restricted by publication type or study 
design. Relevant reviews and clinical studies published on this topic 
were included as well, although not highlighted by our initial search.
Epidemiology
The lack of standardized diagnostic criteria for ABPA limits the 
estimation of prevalence of this condition, which remains speculative. 
In addition, the disease is still misdiagnosed (mostly as pulmonary 
tuberculosis) in developing countries [5]. ABPA occurs almost 
exclusively in patients of both sexes with asthma or CF who have 
concomitant atopy and its diagnosis is based on clinical, biological and 
radiological criteria. The global prevalence of asthma-ABPA patients 
has been estimated to be as high as 2.5%. Denning et al. [6] in addition, 
estimated the global burden of 4,837,000 ABPA patients in a worldwide 
asthma population.
The prevalence of CF-ABPA patients, according to a meta-analysis 
including 45 studies, conducted by Maturu and Agarwal [7], ranges 
from 3% to 25%, with a mean value of 8.9%, with a higher prevalence 
in adults in comparison with children. The wide range of prevalence is 
due to a heterogeneity in diagnostic criteria. Geller et al. [8] reported a 
slightly higher prevalence in male than in female patients with ABPA 
and CF. Other studies on CF-ABPA patients showed a lower age-
related prevalence in patients younger than 5-6 years and an increasing 
prevalence from ages 6 to 20 [9].
Pathogenesis
ABPA is one of many A. fumigatus related diseases and results 
from a hyperreactive immune response to the fungus without the 
tissue invasion that occurs in immunosuppressed patients (invasive 
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Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, occurring mostly in asthmatic and 
cystic fibrosis patients, caused by an abnormal T-helper 2 lymphocyte response of the host to Aspergillus fumigatus 
antigens. ABPA diagnosis is defined by clinical, laboratory and radiological criteria including active asthma, immediate 
skin reactivity to A. fumigatus antigens, total serum IgE levels>1000 IU/mL, fleeting pulmonary parenchymal 
opacities and central bronchiectases that represent an irreversible complication of ABPA. Despite advances in our 
understanding of the role of the allergic response in the pathophysiology of ABPA, pathogenesis of the disease is still 
not completely clear. In addition, the absence of consensus regarding its prevalence, diagnostic criteria and staging 
limits the possibility of diagnosing the disease at early stages. This may delay the administration of a therapy that can 
potentially prevent permanent lung damage. Long-term management is still poorly studied. Present primary therapies, 
based on clinical experience, are not yet standardized. These consist in oral corticosteroids, which control acute 
symptoms by mitigating the allergic inflammatory response, azoles and, more recently, anti-IgE antibodies. The latter 
two are used as a steroid-sparing agent to prolong the remission stage of the disease. Anti-IgE antibodies also have 
immunomodulatory properties. At present, the only way to bypass these limits and allow for an early diagnosis, is 
to assume ABPA in all patients with difficult-to-control asthma or cystic fibrosis. They should then be screened for 
sensitization to A. fumigatus antigens and, if positive, monitored more closely. Future controlled studies are needed 
to standardize present therapy, standardize cut-off values of various investigations, define the role of different novel 
immunomodulatory therapies, define the role of novel assays (such as recombinant A. fumigatus antigens and CCL17) 
and confirm new diagnostic and staging criteria.
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pulmonary aspergillosis (IPA)). ABPA complex pathophysiology 
depends upon both the host’s response and the characteristics of A. 
fumigatus. This saprophytic, spore-forming, and ubiquitous fungus is 
the most common type of outdoor and indoor environmental mold 
with spores that optimally grow at 15°C to 53°C [10]. Spores are easily 
inhaled (2 µm to 5 µm in diameter) through the carina; they settle in 
distal and terminal airways, where they germinate in hyphae, especially 
in favorable environments such as mucus. Hyphae are able to release 
proteases that are responsible for the degradation of the epithelial cell 
layer [11]. As a result, the diffusion of antigens is promoted through the 
bronchial epithelium. Once recognized by antigen presenting cells, the 
latter activate the host immune response by releasing specific cytokines 
and by presenting A. fumigatus antigens to naïve T lymphocytes, 
inducing an exaggerated T-helper class II (Th2) response (specific 
to ABPA) instead of a Th1 response. Notably, Th2 cell priming and 
impairment of macrophage activities are orchestrated by the Th2-
associated chemokine CCL17. In addition, Th2 cytokines (IL-4, IL-5, 
IL-13) stimulate B lymphocytes to produce specific A. fumigatus IgE 
that are responsible for type I hypersensitivity reaction in the airways 
mostly characterized by eosinophil recruitment that causes local 
inflammation.
However, only a small percentage of colonized subjects develops 
sensitization to the fungus and an even smaller subset of those sensitized 
patients progresses towards ABPA [12]. Thus, the development of the 
disease may depend more on the host characteristics, some of which 
are described below.
Above all, several genetic factors implicated in ABPA susceptibility 
have been identified. CF and asthmatic patients, who express HLA-
DR2 and/or HLA-DR5 alleles, are at major risk of developing ABPA. 
By contrast, the HLA-DQ2 genotype seems to provide protection from 
ABPA [13]. In addition, ABPA susceptibility has been associated with 
several genetic polymorphisms [14]. Polymorphism of IL-4RA occurs 
in 95% of ABPA patients and promotes B cells IgE isotype switching 
[15]. IL-10 promoter polymorphisms promote an A. fumigatus specific 
Th2 response [16].
Single Nucleotide Polymorphisms (SNPs) in the collagen region 
of pulmonary surfactant protein A2 (SP-A2) have been correlated 
with higher IgE levels and higher percentages of eosinophilia in ABPA 
patients. The collagen region including these SNPs is likely associated 
with the coding region for receptors of alveolar macrophages implicated 
in host defense against A. fumigatus colonization [17].
Moreover, CFTR gene mutations detected in asthma-ABPA 
patients without CF might be implicated in abnormalities of mucus that 
promote trapping and proliferation of A. fumigatus spores [18]. In fact, 
Lebecque et al. [19] hypothesized that ABPA in pancreatic-sufficient 
adults is a CFTR-related disorder. As ABPA is often associated with 
bronchiectases (that also represent a phenotypic feature of CF), further 
investigations (sweat test) are indicated to exclude milder forms of CF 
in these patients. Finally, among genetically-determined factors, atopy 
represents an important risk factor for ABPA. Other associated atopic 
conditions are highly represented in ABPA patients [20].
Among non-genetic host-related risk factors implicated in 
ABPA pathogenesis, the role of higher cumulative doses of inhaled 
corticosteroids (ICS) has been investigated. In a study conducted by 
Ritz et al. [21] on risk factors for ABPA in 160 CF patients, higher 
cumulative doses of ICS were significantly associated with A. fumigatus 
sensitization, but not with ABPA. Because ABPA, when occurring in 
asthmatic patients, affects mostly corticosteroid-dependent subjects, it 
would be useful to investigate the possible effect of cumulative doses of 
ICS as a risk factor for asthma-ABPA patients as well. In fact, while ICS 
are an effective and safe therapy in asthma patients, at the low doses 
usually required, it is possible to hypothesize that higher doses of ICS 
can impair immune functions, most importantly macrophage killing, 
leading to increased germination of A. fumigatus [9,21].
Finally, new insights into ABPA pathogenesis have been supplied by 
recent investigations on pulmonary microbiome.
Several studies investigating the airways microenvironment of ABPA 
patients reported an association between detection of A. fumigatus and 
other microbes including Alternaria, Candida albicans, Pseudomonas 
aeruginosa and Burkholderia cepacia [9]. More specifically, the evidence 
of a coexistent colonization of A. fumigatus and P. aeruginosa in studies 
conducted on CF-ABPA patients allowed the postulate of a synergistic 
effect of these microbes on lung functions [12].
These results support the hypothesis that some bacterial or fungal 
microbes in the airway microenvironment can promote its colonization 
and sensitization by A. fumigatus. Although the involved microbe-to-
microbe interaction is still unclear, it is possible to suppose that damage 
of bronchial epithelium due to some pathogens can facilitate the 
colonization by secondary microbes.
Diagnosis
ABPA diagnosis presently relies on integrated clinical, radiographic, 
and serologic features (Table 1). There is no single specific and sensitive 
test or universally recognized criteria thus far.
Clinical Features
With the development of ABPA, asthma or CF typically worsens. 
ABPA onset generally presents with exacerbation symptoms resembling 
poorly controlled asthma (increased wheezing, increased coughing) as 
well as expectoration of brown mucous plugs and hemoptysis. These 
symptoms always require an evaluation for ABPA in a patient with 
asthma or CF [20,22].
In some cases, malaise, low-grade fever and weight loss are also 
observed [20], while patients with ABPA exacerbations are rarely 
asymptomatic and may be diagnosed solely on the basis of radiographic 
and/or serologic abnormalities [23].
Clinical presentation in CF-ABPA patients is extremely non-specific 
because it overlaps with the symptoms and signs of CF exacerbations. 
Viscosity of mucus, even more extreme than in CF, is one typical feature 
of ABPA exacerbations. In addition, the latter should be considered 
when the treatment of a suspected bacterial bronchial infection is 
ineffective [4].
Deterioration of lung function, bronchiectases and pulmonary 
fibrosis are considered the most fearsome complications for both 
asthma- and CF-ABPA patients. An unusual manifestation of CF-
ABPA patients may be pneumomediastinum [24].
Findings during physical examination are usually similar to asthma, 
revealing wheezing and a prolonged expiratory phase. Clubbing, 
pulmonary hypertension and cyanosis may be present at advanced 
stages of the disease [11].
Diagnostic criteria for asthma-ABPA patients
Several diagnostic criteria for asthma-ABPA patients have been 
suggested over the past several decades (Table 2). In 1977, Rosenberg 
et al. [25] formulated diagnostic criteria, still widely accepted, that 
included seven relevant findings defined as “primary criteria”: asthma, 
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parenchymal infiltrates, elevated total serum IgE levels, cutaneous 
reactivity to A. fumigatus, serum eosinophilia, precipitating antibodies 
against A. fumigatus and central/proximal bronchiectasis. A few years 
later, eosinophilia and pulmonary infiltrates ceased to be considered 
essential for ABPA diagnosis because these findings can be present only 
during exacerbations [26].
In 1986, Patterson et al. [27] highlighted that bronchiectases, 
considered a major criterion for ABPA diagnosis, can be absent in 
early stage ABPA. Therefore, in 1991, diagnostic criterion was revised 
by classifying ABPA patients into two categories: ABPA-CB (ABPA 
with central bronchiectases) and ABPA-S (ABPA seropositive without 
bronchiectases) [28]. The frequency of exacerbations and the probability 
of permanent lung damage are believed to be lower in patients with 
ABPA-S compared to ABPA-CB patients [20].
Agarwal et al. [23] proposed a new set of diagnostic criteria with 
the aim of overcoming the traditional classification and suggesting an 
optimum cut-off value for total serum IgE levels while not considering 
bronchiectases, which can develop much later in ABPA natural history. 
Agarwal et al. [23] established that ABPA diagnosis should first be 
formulated by the presence of two obligatory criteria — positivity of 
skin prick test and/or elevated serum IgE to A. fumigatus and total 
serum IgE levels >1000 IU/mL and at least two of three “other criteria” 
including precipitins or IgG antibodies to A. fumigatus, radiological 
Findings CF Asthma
Clinical Features
Worsening wheezing Worsening wheezing
Increase in productive cough with expectoration of brown 
mucous plugs 
Increase in productive cough with expectoration of brown mucous 
plugs 
Hemoptysis Hemoptysis
Malaise Malaise
Low-grade fever Low-grade fever 
Weight loss Weight loss
Serological Findings
Skin prick test >3 mm > 3 mm
Total serum IgE levels >500 IU/mL (minimal criteria)>1000 IU/mL (classic criteria) >1000 IU/mL
Serum IgE to A. fumigatus >0.35 KU/L >0.35 KU/L
Eosinophilia not considered >500 cells/μL
Precipitins and Serum IgG to A. 
fumigatust not significant not significant
Recombinant Aspergillus Ag promising data not available
BAT (basophil activation test) promising data not available
CCL17 (serum) promising data not available
Galactomannan (serum) not significant not significant
Radiological Findings
Fleeting parenchymal opacities in upper lobes Fleeting parenchymal opacities in upper lobes 
Central bronchiectases Central bronchiectases
Mucoid impaction Mucoid impaction
Bronchial wall thickening Bronchial wall thickening
Atelectasis Atelectasis
Lobar or whole lung collapse Lobar or whole lung collapse 
End-stage findings: Fibrosis and cavitations End-stage findings: Fibrosis and cavitations
Table 1: Diagnostic findings in CF-ABPA and Asthma-ABPA.
Rosenberg et al. [25] Schwartz and Greenberger [28] Agarwal et al. [23]
Primary criteria: ABPA-CB: Obligatory criteria:
•	 Asthma
•	 Elevated total serum IgE levels 
•	 Immediate skin reactivity to A. fumigatus
•	 Serum eosinophilia
•	 Precipitins
•	 Central bronchiectases
•	 History of pulmonary infiltrates
•	 Asthma 
•	 Positive skin test to A. fumigatus
•	 Elevated Total serum IgE levels 
•	 Serum IgE and IgG to A. fumigatus
•	 Central bronchiectases 
•	 Positive skin test and/or serum IgE to A. 
fumigatus 
•	 Elevated total serum IgE levels 
Other criteria (≥ 2):
•	 Precipitins or serum IgG to A. fumigatus 
•	 Serum eosinophilia
•	 Radiological pulmonary findings consistent with 
ABPA
ABPA-S
•	 Asthma 
•	 Positive skin test to A. fumigatus
•	 Elevated Total serum IgE levels 
•	 Serum IgE and IgG to A. fumigatus
Secondary criteria:
•	 A. fumigatus in sputum
•	 History of brown plugs or flecks expectoration 
•	 Late skin reactivity to A. fumigatus Additional findings:
•	 Mucus plugs 
•	 A. fumigatus in sputum 
•	 Precipitins 
•	 Parenchymal infiltrates
•	 Delayed positive skin test
Table 2: Diagnostic criteria for asthma-ABPA patients.
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pulmonary findings consistent with ABPA, and total eosinophil count 
>500 cells/μL (in patients not treated with steroids) [23].
Diagnostic criteria for CF-ABPA patients
Diagnosis in CF-ABPA patients may be particularly challenging 
because typical clinical and radiological ABPA findings are often present 
at baseline in CF patients. A high level of suspicion for ABPA should be 
kept in CF patients older than 6 years of age. The diagnostic criteria for 
CF-ABPA patients are reviewed extensively and most recently in the CF 
Foundation Consensus Conference (CFFCC) statement where ABPA is 
suggested in case of clinical deterioration (worsening cough, exercise 
intolerance or wheezing, increased sputum and decline in pulmonary 
function test, not attributable to another etiology). This should lead to 
skin testing for A. fumigatus (a wheal >3 mm in diameter is considered 
positive) and measurement of total serum IgE levels (suggestive of ABPA 
if >1000 IU/mL for patients not treated with systemic corticosteroids).
In addition, new or recent radiological findings, at chest imaging, 
not responsive to standard treatment (antibiotics and physiotherapy) 
can help distinguish infiltrates due to ABPA over an active infectious 
process. Total serum IgE levels >500 IU/mL (1200 ng/mL) are 
considered a minimal diagnostic criterion for CF-ABPA patients (Table 
3). In CF patients with highly suspected ABPA and total serum IgE 
value of 200 IU/mL to 500 IU/mL, it is advised to reevaluate IgE levels 
in 1-3 months [22,24].
Clinical Staging of ABPA
ABPA may be progressive. Staging of the disease was first proposed 
by Rosenberg et al. [25] and has been mostly applied in the clinical and 
therapeutic follow-up of asthma-ABPA patients in order to discriminate 
active disease from remission or end-stage bronchiectases, the latter 
leading to progressive lung damage.
Patterson et al. [26] classified ABPA into five stages: acute stage I 
describes patients with elevated total serum IgE levels, eosinophilia and 
infiltrates at chest radiographs; stage II is characterized by the absence 
of radiological findings after discontinuation of oral steroids for more 
than 6 months (remission); recurrent exacerbations define stage III; 
steroid dependent patients are classified in stage IV; stage V defines 
fibrotic disease. Progression from one stage to another is not necessarily 
sequential.
Agarwal et al. [23] proposed a new clinical staging of asthma-
ABPA by introducing a stage 0 for asymptomatic patients diagnosed 
with ABPA after routine investigation, while stage 1 is referred to 
acute ABPA. Stage 2 is described as a “response stage” that includes 
improvement in symptoms, clearing of radiographic opacities and at 
least a 25% decline in total serum IgE levels (generally occurring after 8 
weeks of therapy). Stage 3, occurring in 25% to 50% of ABPA patients, 
is characterized by an increase of 50% in baseline total serum IgE levels 
and associated with clinic-radiological worsening. Baseline total serum 
IgE levels generally refers to the earliest IgE test available or is obtainable 
in the absence of radiological findings during remission (stage 4), which 
is defined by the absence of exacerbations over 6 months. Patients in 
stage 4 require a follow-up with a measurement of total serum IgE levels 
every 3-6 months. Patients with difficult to control ABPA symptoms are 
identified by stage 5, while stage 6 includes patients with widespread 
bronchiectases or fibrosis [23].
Diagnostic Test Findings
Skin testing
In patients with suspected ABPA, skin testing for A. fumigatus 
followed by total serum IgE levels measurement should always be 
performed. A positive Skin Prick Test (SPT) for A. fumigatus is due to 
IgE-mediated response (hypersensitivity) to A. fumigatus antigens and 
it is considered the gold standard screening for ABPA. SPT is highly 
sensitive for A. fumigatus IgE mediated response (90%) but is not 
specific to ABPA: up to 40% of patients without ABPA can demonstrate 
a sensitization to A. fumigatus antigens [29]. In addition, some patients 
may only show hypersensitivity with an intradermal test, which should 
be performed only in case of a negative SPT [23].
Serologic assays
Confirmatory diagnostic serologic assays can be performed in the 
event of a positive SPT. More specifically, measurement of total serum 
IgE levels is useful in both diagnosis and follow up of ABPA.
Total serum IgE levels
Active ABPA is generally excluded in corticosteroid-naïve patients 
with normal total serum IgE levels despite there is no consensus on the 
cut-off value that should be used for the diagnosis of the disease.
In addition, many studies report total serum IgE levels using 
different units, generating difficulties for the interpretation of data. 
Finally, the wide variation in IgE concentration in normal population 
represents an additional challenge in establishing precise cut-off values. 
Despite these limits, a cut-off value >1000 IU/mL (>2400 ng/mL) for 
asthma-ABPA patients has been suggested and employed thereafter in 
several studies [30].
For CF patients the total serum IgE levels suggested by the CFFCC 
that discriminate ABPA patients from sensitized patients is >500 IU/
mL (defined as minimal diagnostic criteria for ABPA) with a sensitivity 
of 70% and specificity of 99%. A level >1000 IU/mL (defined as classic 
diagnostic criteria for ABPA) has a sensitivity of 39% and a specificity 
of 100% [22,23].
Total serum IgE levels are high at diagnosis or during exacerbations, 
but they decrease in the event of remission, glucocorticoids treatment 
and end-stage ABPA. Therefore, diagnosis should be based on the 
earliest IgE test available.
IgE antibodies specific to A. fumigatus
An elevated level of IgE antibodies specific to A. fumigatus is 
considered a characteristic finding of ABPA. A suggested value >0.35 
kU/L should be used as cut-off in discriminating ABPA patients from 
asthmatic patients sensitized to A. fumigatus [31].
Cystic Fibrosis Foundation Consensus Conference [22]
•	 Clinical deterioration (worsening cough, exercise intolerance or wheezing, increased sputum and decline in pulmonary function test, not attributable to another 
etiology).
•	 Positive skin test for A. fumigatus (a wheal>3 mm in diameter) or serum IgE to A. fumigatus
•	 Total serum IgE levels (classic criteria: >1000 IU/mL; minimal criteria: >500 IU/ml)
•	 Precipitins or serum IgG antibodies to A. fumigatus
•	 New or recent radiological findings, at chest imaging, not responsive to standard treatment (antibiotics and physiotherapy)
Table 3: Diagnostic criteria for CF-ABPA patients.
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Serum eosinophilia
Serum eosinophilia is not sensitive or specific, but if present, 
supports a diagnosis of ABPA.
Serum precipitins or specific IgG against A. fumigatus 
Serum precipitins or specific IgG against A. fumigatus are not 
commonly used for ABPA diagnosis, because of a lack of standardized 
laboratory testing [20]. In addition, serum IgG against A. fumigatus may 
not be a specific test for ABPA diagnosis, as high levels are detectable in 
other forms of aspergillosis [23].
Recombinant Aspergillus antigens
The promising role of recombinant Aspergillus antigens in the 
detection of sensitization to A. fumigatus and in the diagnosis of 
ABPA has been recently recognised. Precisely, specific IgE against the 
recombinant allergens Asp f4 (rAsp f4) and/or Asp f6 (rAsp F6) were 
exclusively detected in the serum of individuals with ABPA allowing 
to consider them as specific markers of the disease. While antibodies 
against rAsp f1 and rAsp f3 are elevated in both subjects sensitized 
to A. fumigatus and in ABPA patients. Further studies are required to 
confirm the diagnostic values of these allergens [32,33].
Basophil activation test
Basophil Activation Test (BAT) is a flow cytometry method that 
assess hyper-expression of CD203c on activated basophils in response 
to A. fumigatus. The assay has been proposed as a diagnostic alternative 
to identify A. fumigatus-sensitized CF patients. BAT can better 
discriminate between nonsensitized and A. fumigatus-sensitized CF 
patients when compared to A. fumigatus-IgE specific detection (A. 
fumigatus sensitization cut off >0.35 kU/L) [34].
CCL17
Serum levels of CCL17 (also known as TARC) are elevated in CF 
patients with ABPA. CCL17 is a chemokine produced as a result of 
the antifungal immune response. Recently, elevated levels of CCL17 
have been confirmed as a sensitive and specific marker of ABPA in 
CF patients with diagnostic accuracy greater than total serum IgE and 
recombinant A. fumigatus antigens f4 and f6. In a study conducted by 
Latzin et al. [35], CCL17 levels were elevated in CF-ABPA patients 
even before the development of clinical features of ABPA and before 
total serum IgE elevation. The same authors in another study observed 
significantly higher serum levels of CCL17 in asthma-ABPA and 
CF-ABPA patients when compared to CF patients colonized with or 
sensitized to A. fumigatus [36]. Although the overall results from these 
studies are promising, this new marker requires further investigation in 
order to confirm its clinical potential for early detection of ABPA and 
for disease monitoring.
Galactomannan
Galactomannan (GM) is a polysaccharide component of the A. 
fumigatus cell wall. Testing this antigen with Platelia Aspergillus enzyme 
Immunoessay is the gold standard in the diagnosis of IPA.
Its role in the diagnosis of ABPA needs to be confirmed. In a recent 
study, GM has been tested in the serum of 70 asthma-ABPA patients 
compared with 50 asthmatic patients without ABPA; it has been observed 
that levels of serum GM were not significantly different between the 
two groups. The authors hypothesized that in immunocompromised 
patients with IPA it is possible to detect GM in serum because A. 
fumigatus manages to invade blood vessels, while in ABPA the integrity 
of the immune system prevents fungal dissemination [37]. GM could 
otherwise be detected in the bronchoalveolar fluid and in sputum of 
patients with ABPA.
Radiological Findings
Chest radiographs and Computerized Tomography (CT) are the 
diagnostic tools most widely used for ABPA. The most common findings 
in ABPA are fleeting parenchymal opacities and bronchiectases.
At chest X-Rays, ABPA eosinophilic opacities usually appear as 
a large, homogeneous shadow, more frequently in upper lobes that 
partially or completely disappear after steroid treatment, allowing to 
differentiate from infectious pneumonia.
Mucoid impaction may not be seen at chest radiographs but 
exclusively on high resolution chest CT, considered the most sensitive 
radiological investigation in detecting the full spectrum of ABPA 
findings [38].
Mucoid impaction is characteristic of ABPA exacerbations and 
can be observed as small nodules or as a parallel line spreading from 
the hilum with a rounded distal margin (glove-finger shadow) when 
it opacifies an airway and its branches [39]. Hypodense mucus plugs 
are more commonly described in ABPA, but high-attenuation mucus, 
which suggests chronicity, is a pathognomonic finding of the disease, 
despite being observed in only 20% of patients [40].
Central bronchiectases (CB) are relevant findings that, in 
association with fibrosis, are considered irreversible alterations of 
pulmonary parenchyma. When observed on a chest radiography in an 
en face orientation, they appear like “ring shadows.”
Bronchiectases in ABPA sometimes can be seen also in the 
peripheral lung fields. Although CB of upper lobes are a hallmark 
of ABPA, diagnosis can be made even in their absence because they 
represent a late feature of the disease [27].
Cylindrical, varicose and cystic bronchiectases (the latter two 
specific to ABPA) typically involve multiple bronchi. Their detection 
in three or more lobes is a highly suggestive and helpful clue in 
differentiating asthma and CF without ABPA, where bronchiectases are 
limited to one or two lobes, from asthma-and CF-ABPA [10].
Other radiological findings with CT include bronchial wall 
thickening, atelectasis, lobar or whole lung collapse. Fibrosis and 
cavitations of dilated airways are typically end-stage findings of the 
disease [41].
Pulmonary Function Testing
Because ABPA usually presents in asthmatic and CF patients, 
findings of pulmonary function test are not a sufficient indicator of the 
disease, but they are important to the follow up of ABPA-patients. Mild 
and early ABPA are commonly characterized by a partially reversible 
airflow obstruction, while fixed airflow obstruction reflects progressive 
remodeling of end stage disease [20].
Bronchoscopy
Histo-cytological sampling and fungal culture obtained with 
bronchoscopy do not provide findings considered among the diagnostic 
criteria for ABPA. However, bronchofiberscopy appears to be a useful 
tool in detecting ABPA in patients whose serologic and radiographic 
findings are not typical of ABPA [42]. In these cases, bronchoalveolar 
lavage can be useful to exclude alternate etiologies by showing elevated 
eosinophil counts, elevated IgE levels and A. fumigatus hyphae, while 
lung biopsy may typically show infiltration of airways by eosinophils 
Volume 6 • Issue 4 • 1000361J Pulm Respir MedISSN: 2161-105X JPRM, an open access journal
Citation: Leonardi L, Cinicola BL, Laitano R, Duse M (2016) Allergic Bronchopulmonary Aspergillosis: Diagnostic and Treatment Challenges. J Pulm 
Respir Med 6: 361. doi: 10.4172/2161-105X.1000361
Page 6 of 11
and lymphocytes, mucoid impaction, and fibrotic changes in end-stage 
disease [20,43,44]. In addition, the pathological analysis of mucus 
plugs, obtained in ABPA patients during bronchofiberscopy by suction, 
is commonly characterized by clusters of eosinophils containing fungal 
hyphae in layers. On the contrary, bronchoalveolar lavage washes and 
sputum samples do not offer a reliable culture of A. fumigatus, even 
during exacerbations, while the recovery of A. fumigatus in culture may 
indicate only colonization and is not specific to active disease [44,45]. 
Fiberoptic bronchoscopy may finally have an important therapeutic 
role in removing the mucoid impaction (responsible for atelectasis, 
recurrent exacerbations and proximal collapse) in cases not responsive 
to steroid treatment [4].
Differential diagnosis
The differential diagnosis for ABPA includes ABPM, refractory 
asthma, newly diagnosed CF, infectious pneumonia (especially in 
CF patients), Churg-Strauss syndrome, aspergillus sensitive asthma, 
eosinophilic pneumonia, tuberculosis (most of all in endemic areas), 
bronchocentric granulomatosis and sarcoidosis [20,30].
Therapy
Early diagnosis of ABPA is necessary to initiate prompt treatment 
with the aim of controlling symptoms, preventing exacerbations, 
inducing remission, and potentially preventing significant airway and 
parenchymal destruction.
Management of ABPA typically consists of systemic glucocorticoids, 
administered to attenuate the inflammatory response, and antifungal 
agents, which reduce the fungal load in the airways. Despite that, 
long-term outcomes remain poorly studied. Only a small number 
of randomized controlled trials have been conducted, which did not 
collect useful data on whether or not drugs typically administered slow 
the progression of ABPA to fibrotic lung disease.
Systemic glucocorticoid therapy
Oral corticosteroids in ABPA: Oral corticosteroids (OCS) are 
currently the mainstay of therapy for ABPA. Their anti-inflammatory 
action suppresses the immune hyper-reactivity of ABPA in both 
asthmatic and CF patients. Therapy with OCS leads to an improvement 
of symptoms and resolution of pulmonary infiltrates, and decreases 
total serum IgE levels and peripheral eosinophilia [11], but at 
considerable cost in terms of side effects, if chronically administered, 
such as gastric ulcers, osteoporosis, diabetes, and immune, adrenal and 
growth suppression.
OCS in asthma-ABPA patients: Although several case reports and 
case series supported OCS efficacy in asthma-ABPA patients, there 
are no standardized therapeutic schemes on doses and duration of 
therapy [46]. Two regimens for oral glucocorticoid therapy have been 
suggested in acute ABPA. Greenberger proposed a low-dose regimen 
of daily prednisone 0.5 mg/kg/day for 1-2 weeks, followed by 6 to 8 
weeks of alternate day therapy to be then tapered by 5 mg to 10 mg 
every 2 weeks up to discontinuation based on the individual clinical 
course [10]. Instead, Agarwal et al. [47] proposed a more aggressive 
approach with prednisolone 0.75 mg/kg/day for 6 weeks, then 0.5 mg/
kg/day for 6 weeks, then tapered by 5 mg every 6 weeks to continue 
for a total duration of at least 6-12 months [31]. In order to evaluate if 
higher doses or prolonged therapy with OCS are associated with better 
outcomes, a randomized controlled trial, comparing the two regimens 
by using only prednisolone, has been recently completed. It reported 
that the low dose in OCS is as effective and safer than the high dose in 
treatment of ABPA patients with asthma [47].
OCS in CF-ABPA patients: Therapy for ABPA is challenging 
in patients with CF because both conditions share clinical and 
physiological features [48]. Treatment of CF-ABPA patients is similar 
to asthma-ABPA patients, although higher doses of prednisone are 
recommended.
During CFFCC, guidelines on the treatment of ABPA exacerbations 
in CF patients were issued, suggesting an initial dose treatment of 
prednisone of 0.5 mg/kg/day to 2 mg/kg/day, maximum dose 60 mg, for 
1-2 weeks, then reduced to 0.5 mg/kg/day to 2 mg/kg/day on alternate 
days for 1-2 weeks. A clinical response confirms the diagnosis of 
ABPA exacerbation. Prednisone dose should then gradually be tapered 
within 2-3 months on the basis of clinical, radiological and serological 
findings. In case of relapse, it is suggested to increase OCS or to add 
antifungal therapy [22].
Systemic glucocorticoids are responsible for adverse effects, 
particularly in CF patients who are already at risk of developing 
osteopenia and infections. In long-term patients, vaccination for 
pneumococcus and influenza is advised and integration of calcium 
and Vitamin D should be considered [20]. Therapy must also take into 
account that the pharmacology of many drugs, such as enteric-coated 
prednisolone, is altered in CF patients due to an incomplete absorption 
[22]. Cases of IPA have been reported as a complication of long-term 
corticosteroid therapy in both asthma- and CF-ABPA [49].
In addition, studies show that many patients will require lifelong 
low-dose corticosteroid therapy to control symptoms. Almost 50% 
of patients, after tapering OCS, relapse and 20% to 45% remain 
glucocorticoid-dependent [50]. Therefore, alternative approaches such 
as intravenous or inhaled corticosteroids, azoles or anti-IgE antibodies 
therapy have been developed for the management of ABPA.
Intravenous corticosteroids
Corticosteroid dependence is a state of steroid resistance due to 
down-regulation of steroid receptors in long-term steroid therapy. 
The pulse therapy of high doses of intravenous methylprednisolone 
(HDIVPM) may overcome this effect by limiting the degree of down-
regulation of the receptor and enhancing the clinical efficacy compared 
to daily oral steroids [51].
Pulse steroids therapy efficacy and safety has been demonstrated in 
two asthma-ABPA patients whose exacerbations were unresponsive to 
conventional therapy with OCS and antifungals. Pulse therapy with 1 
g/day of intravenous methylprednisolone for 3 days was able to induce 
clinical stabilization and reduce the dose of OCS therapy within 4-8 
weeks [52]. Efficacy of HDIVPM in the management of CF-ABPA 
patients has been described by Cohen-Cymberknoh et al. [53] in nine 
CF-ABPA patients treated with pulses of HDIVPM of 10 mg/kg/day to 
15 mg/kg/day (max dose 1 g/day) for 3 consecutive days, once a month. 
HDIVPM was associated with antifungal therapy. An improvement in 
respiratory symptoms and pulmonary function and a reduction in total 
serum IgE levels were obtained after the second course of intravenous 
methylprednisolone. HDIVPM was discontinued after 6 to 10 pulses, 
while antifungal therapy continued from 8 months to over 5 years. Only 
mild and transient adverse events were reported.
Inhaled corticosteroids
The use of ICS in controlling ABPA symptoms or preventing 
pulmonary fibrosis is controversial. CFFCC remarked that 
extremely limited information is available on the efficacy of inhaled 
corticosteroids in CF-ABPA patients. Therefore, these drugs should 
not be recommended for initial therapy or for preventing pulmonary 
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fibrosis [22]. In a recent study, 21 glucocorticoid-naïve asthmatic 
patients with ABPA-S have been treated with a combination of 
formoterol/budesonide (24/1600 µg/day) with improvement of 
subjective symptoms in all patients treated. 
Conversely, no patients gained complete control over their asthma, 
while the total serum IgE levels progressively increased in all patients 
over 6 months. Therefore, the authors concluded that ICS can be 
effective in controlling asthma symptoms, while are unable to control 
immunological activity in ABPA [49].
Azoles
Azoles are antifungal agents that have been reported to be a 
valid added therapy to long-term oral steroids in ABPA. Their action 
against airway fungal colonization can reduce antigenic stimulation 
and, consequently, inflammatory response, bringing an improvement 
in symptoms and lung function. Current recommendations suggest 
azoles therapy, combined with OCS, in steroid-dependent patients, 
in patients with recurrent exacerbations, or when corticosteroids 
alone are ineffective in controlling acute symptoms [22,23]. Generally, 
azoles combined with OCS have a steroid-sparing effect that allows the 
reduction of the corticosteroid dose and increases the interval between 
corticosteroid courses [54,55]. A number of different antifungal 
strategies have been tried in ABPA patients.
Nebulized azoles
Inhaled natamycin (5 mg twice daily for one year) has been tested 
in a controlled trial conducted on asthma-ABPA patients by Currie et 
al. [56] without proved steroid sparing effect. Better results on steroid 
sparing effect have been described in few case series and case reports 
on CF-ABPA patients with nebulized amphotericin B whose beneficial 
effects need to be confirmed in larger trials [57].
Systemic azoles
Oral ketaconazole has been used in ABPA [58] but has been 
replaced by itraconazole because of higher efficacy and lower side effects 
of the latter. The dose of azoles in ABPA has never been standardized, 
although a dose of 200 mg twice a day of itraconazole po for recurrent 
16-week courses or long-term therapy have been correlated to clinical 
efficacy [23].
Azoles in asthma-ABPA: In corticosteroid-dependent asthma-
ABPA patients, the effectiveness of itraconazole combined with OCS 
has been demonstrated during a randomized double-blind placebo-
controlled trial using 200 mg of itraconazole po twice daily for 16 
weeks. The efficacy of itraconazole was confirmed by a reduction of at 
least 50% in the oral steroid dose, a decrease of at least 25% in total 
serum IgE levels, and an increase of at least 25% in exercise tolerance. 
In addition, there was an increase in at least one of five pulmonary 
function tests or resolution of pulmonary infiltrates in patients treated 
with itraconazole when compared to the placebo group. Minimal 
adverse effects were reported both in the itraconazole group and in 
the placebo one [59]. In order to analyze the anti-inflammatory effect 
of itraconazole on asthmatic patients with stable ABPA, Wark et al. 
[60] conducted a randomized double-blind placebo-controlled trial 
using 400 mg of itraconazole po per day for 16 weeks. Patients treated 
with itraconazole showed a reduction in sputum eosinophils, sputum 
eosinophil cationic protein levels and in serum IgE and IgG levels to A. 
fumigatus compared to the placebo group. Itraconazole was also able 
to reduce the number of exacerbations requiring oral corticosteroids 
without adverse effects. These data suggest using itraconazole in asthma-
ABPA patients in order to prevent new exacerbations, after controlling 
them with glucocorticoid therapy. Agarwal et al. [23] highlighted that 
neither study reported outcomes for more than 8 months with regard 
to relapses of ABPA. Therefore, the long-term benefits of azole therapy 
remain unknown. 
Azoles in CF-ABPA: There are no randomized controlled trials 
evaluating the use of antifungal therapies for the treatment of CF-
ABPA patients [61]. The CFFCC recommends a dose of 5 mg/kg/day of 
itraconazole po, maximum dose 400 mg/day, for 3-6 months combined 
with OCS in patients who have a poor response to corticosteroids, 
who are corticosteroid-dependent, or where there is evidence of 
corticosteroid toxicity. Liver function should be tested before the 
therapy, after the first month of antifungal therapy and then every 3-6 
months [22].
In both asthma- and CF-ABPA patients, itraconazole serum levels 
(drawn 4 hours after a dose, following at least 1 week of therapy) [22] 
should be monitored to ensure adequate bioavailability and avoid 
toxicity. This therapeutic drug monitoring (TDM) is particularly 
important in patients who do not respond to itraconazole therapy. 
It is also recommended in patients who suffer from liver failure or 
malabsorption, or in subjects taking medication that reduces acid 
production [22]. The maintenance of an itraconazole therapeutic range 
could prevent clinical failure and the development of azole resistance, 
although no clear correlation has been established between drug levels 
and efficacy [23]. However, therapeutic drug monitoring (TDM) of 
itraconazole is limited because its serum concentration is influenced by 
dose-dependent pharmacokinetic [62], drug formulations (capsule, oral 
or intravenous solution) and by individual variations of cytochrome 
P450 activity [63].
Itraconazole minimal steady-state level can be measured by high-
performance liquid chromatography (HPLC) or bioassay. When 
measured by HPLC, the trough level suggested is 0.5 mg/l. The bioassay, 
detecting simultaneously itraconazole and its active metabolite, 
estimates itraconazole levels 2-10 times higher than those obtained by 
HPLC [12,64].
In addition, concomitant therapy should be considered in 
evaluating potential drug-drug interaction between itraconazole and 
several corticosteroids (intravenous methylprednisolone, inhaled 
budesonide or fluticasone) [65]. Itraconazole may increase the activity 
of corticosteroids by inhibiting their metabolism. As a result, onset 
of complications may occur including abnormal adrenocorticotropic 
hormone stimulation and profound immunosuppression leading to 
IPA [66]. Further studies are needed to investigate the possible efficacy 
of itraconazole monotherapy.
Other azoles: Voriconazole and posaconazole are newer azoles 
whose efficacy in asthma- and CF-ABPA patients has been demonstrated 
in some case series [67,68]. Despite that, placebo controlled studies 
have not yet been performed. In addition, these drugs showed a higher 
toxicity compared to itraconazole due to their stronger inhibitory 
effect on hepatic cytochrome P450 enzymes [69]. Serious side effects 
have been described with long-term voriconazole therapy, including 
skin cancer due to photosensitivity, induced by this drug, especially 
in phototypes II-III patients. For these reasons, itraconazole should 
be the first choice for antifungal therapy in ABPA while voriconazole 
or posaconazole should be reserved for patients with poor response or 
experiencing adverse effects to itraconazole. 
Patient Monitoring
Follow up in treated patients with new ABPA diagnosis consists 
in performing total serum IgE levels, chest imaging and lung function 
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test every 6-8 weeks for 1-2 years after the initiation of oral steroids, 
in order to evaluate response to therapy and to identify a possible 
relapse [70]. Successively, total serum IgE levels should be measured 
annually. Clinical effectiveness of therapy is reflected by a decreased 
of 25% to 50% of total serum IgE levels associated to clinical and 
radiological improvement [23]. Since an increase in total serum IgE 
levels may correlate to ABPA exacerbations, it is useful to obtain, while 
patients are in remission stage, a baseline serum level of total IgE to 
be monitored during follow up. Some authors have suggested starting 
corticosteroid therapy even for asymptomatic patients if the total serum 
IgE levels double from the baseline value [27]. However, although even 
an increase by 50% over baseline suggests recurrent disease [71], the 
decision of starting OCS therapy should also take into consideration 
other clinical and radiological parameters. Thus, ABPA therapy 
poses challenging issues. Up to date, no data confirm that combined 
therapy with OCS and azoles can prevent long-term complications. In 
addition, it is not clear if asymptomatic patients can benefit from any 
therapy. Finally, while azoles are effective in preventing ABPA recurrent 
exacerbations, their role in managing acute exacerbations is not clear.
Other Therapeutic Aspects
Omalizumab
Omalizumab is a humanized monoclonal antibody against IgE 
currently used to treat severe asthma with potentially therapeutic 
effect on ABPA. Although serum IgE levels are generally higher than 
1000 IU /mL in ABPA patients and the concentration of anti-IgE 
antibodies required to neutralize this level cannot always be achieved, 
the efficacy of omalizumab in reducing exacerbations, improving 
lung function and reducing OCS in ABPA patients has been proved. 
Efficacy of omalizumab treatment in asthma-ABPA patients has been 
reported in many case series and case reports [72-78]. The reduction 
of exacerbations and of total serum IgE levels has generally been 
demonstrated with a dose of 375 mg every 2 weeks for a period of 12-
24 months. A reduction of OCS treatment was described in all patients 
treated. Only one patient in Tillie-Leblond et al. [73] study was not 
able to reduce OCS dose. Discontinuation of OCS during omalizumab 
treatment has been described in adult asthmatic patients with ABPA 
[73,74,77]. A randomized placebo controlled trial conducted by 
Voskamp et al. [79] on asthma-ABPA patients demonstrated clinical 
improvement, decreased basophil reactivity to A. fumigatus, decreased 
basophil FcɛR1 and surface-bound IgE levels after a 3-month therapy 
with 750 mg/monthly of omalizumab. Aside from binding IgE, 
omalizumab downregulates the cell-surface high affinity IgE receptor 
FcɛR1 on basophils. As a result, omalizumab decreases basophil 
sensitivity and reactivity to A. fumigatus antigens [79].
Also, several case reports on CF-ABPA patients treated with 
omalizumab described both reduction of the number of exacerbations 
and improvement in lung function. All patients evaluated in these 
studies were also able to discontinue OCS [80-86].
These results were not confirmed by the only randomized, double-
blind, placebo-controlled study conducted in order to assess the 
efficacy of omalizumab as a steroid-sparing agent in CF-ABPA patients. 
The study was in fact stopped prematurely due to the inability to recruit 
patients (the total number of patients recruited in the omalizumab group 
for the blinded phase was 9) and due to a high drop-out: 5 subjects did 
not continue the study either because of an adverse event (n=1), a lack 
of efficacy of treatment (n=1), or unspecified administrative problems. 
Few side effects have been described in six of nine (66.67%) subjects in 
the omalizumab group in the blinded phase, including distal intestinal 
obstruction syndrome (n=1), infective pulmonary exacerbation of 
cystic fibrosis (n=5), lower respiratory bacterial tract infection (n=1) 
and haemoptysis (n =1) [87].
Since almost a decade, omalizumab has been suggested by Global 
Initiative for Asthma (GINA) guidelines as an added therapy for 
severe asthmatic patients, older than 5 years, dependent from inhaled 
corticosteroid therapy. This treatment may have prevented development 
of ABPA in asthmatic patients. To our knowledge no studies have been 
conducted to investigate this correlation.
ABPA Complications
Recurrent exacerbations, due to either mucoid impaction or 
worsening of airflow limitation, are the most common complications in 
ABPA [23]. Untreated ABPA, in addition, can lead to the development 
of widespread bronchiectasis and chronic pulmonary aspergillosis 
(CPA).
CPA, consisting in pulmonary and pleural fibrosis and pulmonary 
cavitations, is responsible for severe complications including pulmonary 
hypertension and cor pulmonale.
Massive hemoptysis and pneumothorax, potentially life-threatening 
conditions, can also complicate the course of ABPA, mostly in CF-
ABPA patients [22].
IPA, generally occurring in immunodeficient subjects, has been 
anecdotically described as an ABPA complication only in patients with 
prolonged, high-dose corticosteroid therapy. In the event of IPA, A. 
fumigatus infection may disseminate hematogenously to other organs, 
including the brain, leading to life-threatening conditions such as 
cerebral infarctions and intracranial hemorrhage [88,89].
Acute hypoxemic respiratory failure, due to large airway collapse 
because of mucus impaction, represents the most fearsome life-
threatening condition in ABPA. In these patients, therapeutic 
bronchoscopy (either fiberoptic or rigid) may be indicated, depending 
on the severity of respiratory failure, to remove the mucoid impaction 
responsible for proximal collapse [23].
Environmental control by allergen avoidance
A. fumigatus is ubiquitous. Certain aggravating factors, such as 
environmental humidity and temperature, influence home fungal 
growth, while some activities like gardening and cleaning dusty 
environments increase the exposure to this fungus. Despite ABPA 
incidence has not been definitively correlated with environmental A. 
fumigatus spore counts, an increase of the latter, when total mold counts 
are high, has been described. Therefore, it is possible to hypothesize 
that controlling environmental factors contributing to the growth of A. 
fumigatus can prevent or reduce the antigens exposure to susceptible 
patients [90].
Conclusions
Despite advances in our understanding of the role of the allergic 
response in the pathophysiology of ABPA, limited evidence exists 
on the pathogenesis of the disease. In addition, early diagnosis of the 
disease is challenged by the absence of consensus regarding diagnostic 
criteria, staging and cut-off values of serologic assays. This may delay 
the administration of a therapy that can potentially prevent permanent 
lung damage. At present, the only way to allow for an early diagnosis 
is to routinely investigate all asthmatic and cystic fibrosis patients 
for ABPA. Future controlled studies are needed to confirm new 
diagnostic and staging criteria and to standardize cut-off values of 
various investigations, while the promising role of novel assays (such 
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as recombinant Aspergillus antigens and CCL17) need to be confirmed.
In addition, because present primary therapies are mostly based 
on clinical experience and limited by significant side-effects, it is 
important to standardize current therapy, while conducting trials on 
novel immuno-modulatory therapies, including monoclonal antibodies 
directed against Th2 cytokines.
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